Denosumab Therapy Associated With Poorer Bone Mineral Density Outcomes - Rheumatology Advisor

Researchers analyzed bone mineral density changes following denosumab therapy for osteoporosis.

Compared with short-duration (up to 3 years) and long-duration (more than 7 years) treatment, medium-duration treatment (4 to 6 years) with denosumab is associated with inferior bone mineral density … [+2674 chars]

full article...